These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17155983)

  • 1. S-allylcysteine, a water-soluble garlic derivative, suppresses the growth of a human androgen-independent prostate cancer xenograft, CWR22R, under in vivo conditions.
    Chu Q; Lee DT; Tsao SW; Wang X; Wong YC
    BJU Int; 2007 Apr; 99(4):925-32. PubMed ID: 17155983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
    Chen CT; Gan Y; Au JL; Wientjes MG
    Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer.
    Howard EW; Ling MT; Chua CW; Cheung HW; Wang X; Wong YC
    Clin Cancer Res; 2007 Mar; 13(6):1847-56. PubMed ID: 17363541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression.
    Chu Q; Ling MT; Feng H; Cheung HW; Tsao SW; Wang X; Wong YC
    Carcinogenesis; 2006 Nov; 27(11):2180-9. PubMed ID: 16675472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
    Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
    Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
    Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
    Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
    Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
    Chua CW; Lee DT; Ling MT; Zhou C; Man K; Ho J; Chan FL; Wang X; Wong YC
    Int J Cancer; 2005 Dec; 117(6):1039-48. PubMed ID: 15986440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
    Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
    Galkin AV; Mullen L; Fox WD; Brown J; Duncan D; Moreno O; Madison EL; Agus DB
    Prostate; 2004 Nov; 61(3):228-35. PubMed ID: 15368474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
    Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
    Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
    Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
    Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME; Goddard L; Smith C; Nicholson RI
    Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
    Howard EW; Lee DT; Chiu YT; Chua CW; Wang X; Wong YC
    Int J Cancer; 2008 May; 122(9):1941-8. PubMed ID: 18183597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
    Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
    Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
    Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.